Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.61)
# 236
Out of 4,996 analysts
50
Total ratings
61.22%
Success rate
27.98%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $54 → $64 | $47.10 | +35.88% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $23.92 | +42.14% | 5 | Aug 27, 2025 | |
| SCPH scPharmaceuticals | Downgrades: Hold | $6 | $5.65 | +6.19% | 3 | Aug 26, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $9.04 | +54.87% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $3.33 | +290.39% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $8.18 | +34.47% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $6.94 | +58.50% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $2.01 | +49.25% | 1 | Jul 1, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.99 | +134.11% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $11.78 | +44.31% | 3 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $28 | $21.27 | +31.64% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $17.89 | +118.00% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $1.39 | +475.54% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.75 | +95.44% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $3.95 | +52.09% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $6.94 | +72.91% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.98 | +43.27% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $15.34 | +49.93% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.64 | +87.09% | 2 | Jul 11, 2023 |
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $47.10
Upside: +35.88%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $23.92
Upside: +42.14%
scPharmaceuticals
Aug 26, 2025
Downgrades: Hold
Price Target: $6
Current: $5.65
Upside: +6.19%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $9.04
Upside: +54.87%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $3.33
Upside: +290.39%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $8.18
Upside: +34.47%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.94
Upside: +58.50%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $2.01
Upside: +49.25%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.99
Upside: +134.11%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $11.78
Upside: +44.31%
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $21.27
Upside: +31.64%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $17.89
Upside: +118.00%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $1.39
Upside: +475.54%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.75
Upside: +95.44%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $3.95
Upside: +52.09%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $6.94
Upside: +72.91%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $6.98
Upside: +43.27%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $15.34
Upside: +49.93%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.64
Upside: +87.09%